=> b reg FILE 'REGISTRY' ENTERED AT 14:16:34 ON 06 JUN 2007 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 5 JUN 2007 HIGHEST RN 936615-27-9 DICTIONARY FILE UPDATES: 5 JUN 2007 HIGHEST RN 936615-27-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> d que sta 117



REP G1=(1-20) C VAR G2=O/S NODE ATTRIBUTES: DEFAULT MLEVEL IS ATOM DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES: RING(S) ARE ISOLATED OR EMBEDDED NUMBER OF NODES IS 23

STEREO ATTRIBUTES: NONE

L17 35 SEA FILE=REGISTRY SSS FUL L15

100.0% PROCESSED 25388 ITERATIONS SEARCH TIME: 00.00.01

35 ANSWERS

=> b hcap

FILE 'HCAPLUS' ENTERED AT 14:16:47 ON 06 JUN 2007 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 6 Jun 2007 VOL 146 ISS 24 FILE LAST UPDATED: 5 Jun 2007 (20070605/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d bib abs hitstr retable 113

```
L13 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2007 ACS on STN
```

2004:610069 HCAPLUS AN

DN 141:140475

ΤI Preparation of macrocyclic β -secretase inhibitors for treatment of Alzheimer's disease

IN Coburn, Craig A.; Stachel, Shawn J.; Vacca, Joseph P.

PA Merck & Co., Inc., USA

SO PCT Int. Appl., 44 pp.

CODEN: PIXXD2

DT Patent

English LA

FAN.	CNT 1															
	PATENT	NO.				D DATE	;		APPL	ICAT	ION :	NO.		D	ATE	
														-		
PI	WO2004062625			A2	2004	0729	29 2004WO-US00085				20040102					
	WO20040	6262	5		A3	2005	0331									
	₩:					AT, AU,										
		CN,	CO,	CR,	CU,	CZ, DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FI,	GB,	GD,
		GE,	GH,	GM,	HR,	HU, ID,	IL,	IN,	IS,	JP,	KE,	KG,	ΚP,	KR,	KZ,	LC,
		LK,	LR,	LS,	LT,	LU, LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ		
AU2004204692			A1	2004	20040729 2004AU-0204692				20040102							
	CA2512111			A1	A1 20040729 2004CA-2512111				20040102							
	EP1583750			. A2	2005	20051012 2004EP-0700071				20040102						
	R:	ΑT,	BE,	CH,	DE,	DK, ES,	FR,	GB,	GR,	IT,	LI,	LU,	NL,	SE,	MC,	PT,
		IE,	SI,	LT,	LV,	FI, RO,	MK,	CY,	AL,	TR,	BG,	CZ,	EE,	HU,	SK	•
	JP20065	1588	1		T	2006	0608		2006	JP-0	5007	80		20	0040	102
US2006058278						76		20050706								
PRAI	2003US-	4386	30P		P	2003	0107					-				
	2004WO-	USOO	085		W	2004	0102									
OS GI	OS MARPAT 141:140475				••	2001										

AB Macrocycles of formula I [R1 = H, alkyl, cycloalkyl, (substituted) Ph, etc.; R2 = H, alkyl-SO2N(alkyl), CN, halo, etc.; R3 = CH2OH, CHO, acyl, CH2NH2, CONH2, etc.; X = (CH2)m; m = 1-4] are prepared which are inhibitors of the β -secretase enzyme and are useful in the treatment or prevention of diseases in which β -secretase is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compns. comprising these compds. and the use of these compds. and compns. in the prevention or treatment of such diseases in which β -secretase is involved. Thus, II was prepared in several steps from dibenzyl 5-aminoisophthalate, dl-meta-tyrosine and Boc-L-phenylglycinol. The compds. had IC50 values from about 1 nM to 1 μ M against β -secretase.

IT 725725-36-0P

CN

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of macrocyclic β -secretase inhibitors for treatment of Alzheimer's disease)

RN 725725-36-0 HCAPLUS

Butanamide, 2-[[[(4S,13S)-13-methyl-18-[methyl(methylsulfonyl)amino]-2,15-dioxo-11-oxa-3,14-diazatricyclo[14.3.1.16,10]heneicosa-1(20),6,8,10(21),16,18-hexaen-4-yl]methyl]amino]-N-(2-methylpropyl)-,(2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

=> d bib abs hitind fhitstr retable 127 tot

L27 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN AN 2006:1149497 HCAPLUS

```
DN
     146:19371
ΤI
     Macrocyclic Inhibitors of \beta-Secretase: Functional Activity in an
     Animal Model. [Erratum to document cited in CA145:465146]
     Stachel, Shawn J.; Coburn, Craig A.; Sankaranarayanan, Sethu; Price, Eric A.; Wu, Guoxin; Crouthamel, Michelle; Pietrak, Beth L.;
ΑU
     Huang, Qian; Lineberger, Janet; Espeseth, Amy S.; Jin, Lixia; Ellis, Joan;
     Holloway, M. Katharine; Munshi, Sanjeev; Allison, Timothy; Hazuda, Daria;
     Simon, Adam J.; Graham, Samuel L.; Vacca, Joseph P.
CS
     Department of Medicinal Chemistry, Biological Chemistry, Molecular Systems
     and Structural Biology, Merck Research Laboratories, West Point,
     PA, 19486, USA
SO
     Journal of Medicinal Chemistry (2006), 49(24), 7252
     CODEN: JMCMAR; ISSN: 0022-2623
PR
     American Chemical Society
DT
     Journal
     English
LA
AB
     Guoxin Wu and Michelle Crouthamel were inadvertently omitted from the
     author list. Their affiliation is the Department of Biol. Chemical,
     represented by the double dagger symbol in the paper. The correct author
     list is given.
CC
     1-3 (Pharmacology)
     Section cross-reference(s): 34
TΤ
     725725-37-1P 725725-38-2P
                                  847157-19-1P
                                                  847157-32-8P
     913625-93-1P 913626-00-3P
     RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
     (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
        (macrocyclic inhibitors of β-secretase and functional activity in
        an animal model (Erratum))
     12135-22-7P, Pearlman's catalyst
                                         50765-19-0P, Methyl-3-Iodo-5-
     nitrobenzoate
                    184176-05-4P
                                    217314-45-9P, Methyl 3-amino-5-iodobenzoate
     725725-42-8P
                    725725-51-9P
                                    725725-52-0P 725725-55-3P
     760894-94-8P
                    847157-47-5P
                                    847157-48-6P
                                                    847157-49-7P
                                                                   847157-50-0P
     847157-51-1P
                    847157-52-2P · 847157-53-3P
                                                    847157-54-4P
                                                                   913625-97-5P
     913626-02-5P
                    913626-03-6P
                                    913626-04-7P
                                                    913626-05-8P
                                                                   913626-06-9P
     913626-07-0P
                    913626-08-1P
                                    913626-09-2P
                                                    913626-11-6P
                                                                   913626-12-7P
     913626-13-8P
                    913626-15-0P
                                    913626-16-1P
                                                    913626-17-2P
     RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
     (Reactant or reagent)
        (macrocyclic inhibitors of \beta-secretase and functional activity in
        an animal model (Erratum))
IT
     725725-37-1P
     RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
     (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
        (macrocyclic inhibitors of \beta-secretase and functional activity in
        an animal model (Erratum))
RN
     725725-37-1 HCAPLUS
CN
     Methanesulfonamide, N-[(4S)-4-(hydroxymethyl)-2,15-dioxo-11-oxa-3,14-
     diazatricyclo[14.3.1.16,10] heneicosa-1(20),6,8,10(21),16,18-hexaen-18-y1]-
     N-methyl- (CA INDEX NAME)
```

Absolute stereochemistry.

```
L27 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN AN 2006:908572 HCAPLUS DN 145:465146
```

TI Macrocyclic Inhibitors of $\beta\text{-Secretase:}$ Functional Activity in an Animal Model

AU Stachel, Shawn J.; Coburn, Craig A.; Sankaranarayanan, Sethu; Price, Eric A.; Pietrak, Beth L.; Huang, Qian; Lineberger, Janet; Espeseth, Amy S.; Jin, Lixia; Ellis, Joan; Holloway, M. Katharine; Munshi, Sanjeev; Allison, Timothy; Hazuda, Daria; Simon, Adam J.; Graham, Samuel L.; Vacca, Joseph P.

CS Department of Medicinal Chemistry, Biological Chemistry, Molecular Systems and Structural Biology, Merck Research Laboratories, West Point, PA, 19486, USA

SO Journal of Medicinal Chemistry (2006), 49(21), 6147-6150 CODEN: JMCMAR; ISSN: 0022-2623

PB American Chemical Society

DT Journal

LA English

AB A macrocyclic inhibitor of β -secretase was designed by covalently crosslinking the P1 and P3 side chains of an isophthalamide-based inhibitor. Macrocyclization resulted in significantly improved potency and phys. properties when compared to the initial lead structures. More importantly, these macrocyclic inhibitors also displayed in vivo amyloid lowering when dosed in a murine model.

CC 1-3 (Pharmacology)

Section cross-reference(s): 34

IT 725725-37-1P 725725-38-2P 847157-19-1P 847157-32-8P 913625-93-1P 913626-00-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(macrocyclic inhibitors of $\beta\mbox{-secretase}$ and functional activity in an animal model)

IT 12135-22-7P, Pearlman's catalyst 50765-19-0P, Methyl-3-Iodo-5nitrobenzoate 184176-05-4P 217314-45-9P, Methyl 3-amino-5-iodobenzoate 725725-42-8P 725725-51-9P 725725-52-0P 725725-53-1P 725725-55-3P 760894-94-8P 847157-47-5P 847157-48-6P 847157-49-7P 847157-50-0P 847157-51-1P 847157-52-2P 847157-53-3P 847157-54-4P 913625-97-5P 913626-02-5P 913626-03-6P 913626-04-7P 913626-06-9P 913626-05-8P 913626-07-0P 913626-08-1P 913626-09-2P 913626-11-6P 913626-12-7P 913626-13-8P 913626-15-0P 913626-16-1P 913626-17-2P 928823-83-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(macrocyclic \bar{i} nhibitors of β -secretase and functional activity in an animal model)

TT 725725-37-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(macrocyclic inhibitors of β -secretase and functional activity in an animal model)

RN 725725-37-1 HCAPLUS

Methanesulfonamide, N-[(4S)-4-(hydroxymethyl)-2,15-dioxo-11-oxa-3,14diazatricyclo[14.3.1.16,10]heneicosa-1(20),6,8,10(21),16,18-hexaen-18-yl]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.

-			-		ı
υ	1.	ם.ו	. н	LE	•

Referenced Author (RAU)	Year (RPY)	VOL (RVL)		Referenced Work (RWK)	Referenced File
Beher. D	+====- 2005	+====- 14	+=====· 1385	+=====================================	
Best, B	2005	313	902	Pharmacol Exp Ther	HCAPLOS
Brady, S	2003	14	601	Bioorg Med Chem Lett	 UCADIJIC
Cai, H	2001	4	233	Nat Neurosci	HCAPLUS
Coburn, C	2006	16	3635	Bioorg Med Chem Lett	
Goate, A		349	523	Nature	IICAF EUS
Hannessian, S	2006	49	4544	J Med Chem	
Hardy, J	1997	349	_	Proc Natl Acad Sci U	:
Hu, X	2004	47	4941	J Med Chem	HCAPLUS
Lamb, B	1993	5	22	Nat Genet	HCAPLUS
Lamb, B	1993	5	22	Nature Genetics	HCAPLUS
Milano, J	2004	82	341	Toxicol Sci	HCAPLUS
Roberds, S	2001	10	1317	Hum Mol Genet	HCAPLUS
Rojo, I	2006	16	191	Bioorg Med Chem Lett	
Sankaranarayanan, S	2006			10th International c	
Savage, M	1998	18	1743	J Neurosci	HCAPLUS
Scholl, M	1999	1	953	Org Lett	HCAPLUS
Searfoss, G	2003	278	46107	J Biol Chem	HCAPLUS
Selkoe, D	1996	271	18295	J Biol Chem	HCAPLUS
Selkoe, D	1999	399A	23	Nature	i
Simon, A	2005			2005 AD/PD meeting	ĺ
Sinha, S	1999	96	11049	Proc Natl Acad Sci U	HCAPLUS
Stachel, S	2006	16	641	Bioorg Med Chem Lett	HCAPLUS
Stachel, S	2004	47	6117	J Med Chem	
Stachel, S	2004	47	6447	J Med Chem	HCAPLUS
Thompson, L	2005	11	3383	Curr Pharm Des	HCAPLUS
Tilley, J	1991	34	1125	J Med Chem	HCAPLUS
Tsantrizos, Y	2003	42	1356	Angew Chem, Int Ed	HCAPLUS

ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN L27

AN 2004:610069 HCAPLUS

DN 141:140475

TI Preparation of macrocyclic β -secretase inhibitors for treatment of Alzheimer's disease

IN Coburn, Craig A.; Stachel, Shawn J.; Vacca, Joseph P.

PΑ

Merck & Co., Inc., USA PCT Int. Appl., 44 pp. SO

CODEN: PIXXD2

```
DT
     Patent
LA
      English
FAN.CNT 1
      PATENT NO.
                             KIND
                                     DATE
                                                   APPLICATION NO.
                                                                              DATE
                             ----
                                     -----
                                                   -----
                                                                              -----
ΡI
     WO2004062625
                              A2
                                     20040729
                                                   2004WO-US00085
                                                                              20040102 <--
     WO2004062625
                              A3
                                     20050331
          W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
               CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
               GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ
     AU2004204692
                                     20040729
                                                   2004AU-0204692
                              A1
                                                                              20040102 <--
     CA---2512111
                              A1
                                     20040729
                                                   2004CA-2512111
                                                                              20040102 <--
     EP---1583750
                              A2
                                     20051012
                                                   2004EP-0700071
                                                                              20040102 <--
          R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     JP2006515881
                              Т
                                     20060608
                                                   2006JP-0500780
                                                                              20040102 <--
     US2006058278
                              A1
                                                   2005US-0541476
                                     20060316
                                                                              20050706 <--
PRAI 2003US-438630P
                              Р
                                     20030107
                                                <--
     2004WO-US00085
                              W
                                     20040102 <--
OS
     MARPAT 141:140475
GI
```

$$R^2$$
 $N-Me$
 R^3
 Ph
 NH
 HN
 R^3
 Ph
 NH
 HN
 CH_2-OH

AB Macrocycles of formula I [R1 = H, alkyl, cycloalkyl, (substituted) Ph, etc.; R2 = H, alkyl-SO2N(alkyl), CN, halo, etc.; R3 = CH2OH, CHO, acyl, CH2NH2, CONH2, etc.; X = (CH2)m; m = 1-4] are prepared which are inhibitors of the β -secretase enzyme and are useful in the treatment or prevention of diseases in which β -secretase is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compns. comprising these compds. and the use of these compds. and compns. in the prevention or treatment of such diseases in which β -secretase is involved. Thus, II was prepared in several steps from dibenzyl 5-aminoisophthalate, dl-meta-tyrosine and Boc-L-phenylglycinol. The compds. had IC50 values from about 1 nM to 1 μ M against β -secretase.

IC ICM A61K

CC 28-23 (Heterocyclic Compounds (More Than One Hetero Atom))
 Section cross-reference(s): 1, 63

IT 725725-35-9P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of macrocyclic β -secretase inhibitors for treatment of Alzheimer's disease)

IT 725725-31-5P 725725-32-6P 725725-33-7P 725725-34-8P 725725-36-0P 725725-37-1P 725725-38-2P 725725-39-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

L9 L10		
		37 C30H43N5O6S
TTT		2 L10 AND NRRS>=3 SEL RN 1
L12		1 E1 AND L11
	FILE	'HCAPLUS' ENTERED AT 13:47:07 ON 06 JUN 2007
L13		1 L12
	FILE	'REGISTRY' ENTERED AT 13:47:26 ON 06 JUN 2007
L14		STR
L15		STR L14
L16		1 L15
L17		35 L16 FULL
		SAV TEM J476C1/A L17
		SEL RN 4-15
L18		12 E2-13 AND L17 12 L18 AND L8
L19		12 L18 AND L8
	FILE	'HCAPLUS' ENTERED AT 14:12:55 ON 06 JUN 2007
L20		3 L18
	FILE	'HCAOLD' ENTERED AT 14:13:29 ON 06 JUN 2007
L21		0 L18
	בידובי	'BIOSIS' ENTERED AT 14:13:40 ON 06 JUN 2007
L22	LIDE	0 L18
1122		0 110
	FILE	'USPATFULL, USPAT2' ENTERED AT 14:13:46 ON 06 JUN 200'
L23		1 L18
	FILE	'MEDLINE' ENTERED AT 14:14:08 ON 06 JUN 2007
L24		0 L18
	FILE	'EMBASE' ENTERED AT 14:14:12 ON 06 JUN 2007
L25		0 L18
		LUCARUMO ENTERRA ATTACAMA CONTRA CONT
	L.T.P.E.	'HCAPLUS' ENTERED AT 14:14:52 ON 06 JUN 2007
L26		3 L13, L20
L27		3 L26 AND L1-6

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(preparation of macrocyclic β -secretase inhibitors for treatment of Alzheimer's disease)

IT 34260-70-3P 725725-40-6P 725725-41-7P 725725-42-8P 725725-44-0P 725725-46-2P 725725-47-3P 725725-48-4P 725725-49-5P 725725-50-8P 725725-51-9P 725725-52-0P

725725-53-1P 725725-54-2P 725725-55-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of macrocyclic β -secretase inhibitors for treatment of Alzheimer's disease)

IT 725725-35-9P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of macrocyclic β -secretase inhibitors for treatment of Alzheimer's disease)

725725-35-9 HCAPLUS RN

CN Methanesulfonamide, N-[(4S,13S)-4-(hydroxymethyl)-13-methyl-2,15-dioxo-11oxa-3,14-diazatricyclo[14.3.1.16,10]heneicosa-1(20),6,8,10(21),16,18hexaen-18-yl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

=> d his

(FILE 'HOME' ENTERED AT 13:36:36 ON 06 JUN 2007)

FILE 'HCAPLUS' ENTERED AT 13:36:44 ON 06 JUN 2007

1 US20060058278/PN OR (US2005-541476 OR WO2004-US00085 OR US2003-L1 E COBURN C/AU

1.2 2 E3

E COBURN CRAIG/AU

L3 71 E3-5

E STACHEL S/AU

L4 57 E3-4,E8-10 E VACCA J/AU

193 E3,E6,E9-14

L5 L6 34202 MERCK/CS, PA

FILE 'REGISTRY' ENTERED AT 13:39:40 ON 06 JUN 2007

FILE 'HCAPLUS' ENTERED AT 13:39:45 ON 06 JUN 2007

L7 TRA L1 1- RN : 36 TERMS

FILE 'REGISTRY' ENTERED AT 13:39:45 ON 06 JUN 2007 L8 36 SEA L7

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	13	(coburn stachel vacca).in. and macrocyclic.ti.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/06 15:14

Page 1